Prana Biotechnology EPS - Earnings per Share 2010-2021 | ATHE

Prana Biotechnology eps - earnings per share from 2010 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Prana Biotechnology Annual EPS
2021 $-0.40
2020 $-0.60
2019 $-0.86
2018 $-0.72
2017 $-0.64
2016 $-0.64
2015 $-3.52
2014 $-1.74
2013 $-1.44
2012 $-1.14
2011 $-1.56
2010 $-1.14
2009 $-1.86
Prana Biotechnology Quarterly EPS
2021-12-31 $0.00
2021-06-30 $0.00
2020-12-31 $0.00
2020-06-30 $0.00
2019-12-31 $0.00
2019-06-30 $0.00
2018-12-31 $0.00
2018-06-30 $0.00
2017-12-31 $0.00
2017-06-30 $0.00
2016-12-31 $0.00
2016-06-30 $0.00
2015-12-31 $0.00
2015-06-30 $0.00
2014-12-31 $0.00
2014-06-30 $0.00
2013-12-31 $0.00
2013-06-30 $0.00
2012-12-31 $0.00
2012-06-30 $0.00
2011-12-31 $0.00
2011-06-30 $0.00
2010-12-31 $0.00
2010-06-30 $0.00
2009-12-31 $0.00
2009-06-30 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00